• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Management buyout of Synexus seeks to expand global network of sites

Management buyout of Synexus seeks to expand global network of sites

February 23, 2015
CenterWatch Staff

Synexus, one of the largest international investigative site networks, with 25 dedicated research centers in eight countries including the U.K., Germany, Poland and South Africa, has completed a management buyout with an eye toward expanding into the U.S., Asia and South America.

Lyceum Capital, which has owned Synexus since 2007, sold its ownership in the Manchester, U.K.-based company to the management team, led by Christophe Berthoux, M.D., CEO, with the backing of private equity investor Lloyds Development Group (LDC), part of Lloyds Banking Group.

Financial terms of the transaction were not announced, but several British newspapers, including the London Telegraph, suggested Synexus management and LDC paid Lyceum approximately $128 million.

Ged Gould, LDC’s director and co-head of its Manchester office, said the deal comes as the pharmaceutical industry and the rapidly expanding biotech sector are set for significant growth driven by aging populations and increased R&D.

"Christophe and the management team have done a fantastic job in building an international network in recent years, and we are eager to further support the business break into new markets as it targets opportunities in the U.S., South America and Asia," Gould said in a statement. “We believe this is a particularly good sector, as pharma continues to outsource their development activity.”

Under Berthoux, the company has expanded by acquiring smaller facilities, including its fourth site in South Africa, citing customer demand for more trial capacity in Africa.

Partnering with LDC “will give us the firepower to continue expanding our international network and to broaden the number of therapy areas we offer our pharma and CRO clients,” Berthoux said in a statement. “We are very grateful to Lyceum. They had the business knowledge and expertise that has helped us transform the company into a professional organization. The partnership with LDC marks the next phase in our ambitious growth plans.”

Last summer, Synexus was identified as a “Hyper growth Business” by GrowthAccelerator, the U.K. government-backed business growth advisory service.

Expansions since 2011 have included new site openings in the U.K., Bulgaria, Ukraine and Romania. Synexus said its 25 sites have increased trial access to more than 68 million potential patients. Synexus conducts predominantly phase III clinical trials in cardiovascular, metabolic (diabetes and obesity), musculoskeletal, respiratory and CNS (dementia and pain) indications.

For its fiscal year ending December 2014, Synexus reported revenue of $63 million and profits of $12 million, a 140% increase since 2011.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing